Objectives: We wished to study the resistance profile of etravirine, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) active against common human immunodeficiency virus type-1 (HIV-1) drug-resistant strains.
Introduction
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are an important component of highly active antiretroviral therapy (HAART) for treatment of HIV infection. 1, 2 Regimens containing either efavirenz or nevirapine have become preferred therapy options for treatment-naive individuals and have gained increased popularity over protease inhibitor-based antiretroviral therapy. However, a low genetic barrier towards resistance of first-generation NNRTIs may limit their use. 3 Secondgeneration NNRTIs such as etravirine can salvage patients who have failed first-line NNRTI-containing antiretroviral regimens.
Etravirine is an approved dianilinopyrimidine (DAPY) compound that can bind to HIV reverse transcriptase (RT) that contains mutations that confer resistance to first-generation NNRTIs. 4 -9 In vitro studies show that etravirine displays a high genetic barrier for resistance, requiring the accumulation of several (at least three) NNRTI-associated mutations for highlevel resistance to become manifest. 5,7 -9 The DUET clinical trials have identified 17 resistance-associated mutations (RAMs), comprising V90I, A98G, L100I, K101E/H/P, V106I, E138A, V179D/F/T, Y181C/I/V, G190A/S and M230L, that confer diminished susceptibility to etravirine. 8, 9 A system for weighted scoring has been proposed, with the 17 etravirine RAMs having differential effects based on clinical response (3.0, Y181I/V; 2.5, L100I, K101P, Y181C and M230L; 1.5, V106I, V179F, E138A and G190S; and 1.0, V90I, A98G, K101E/H, V179D/T and G190A). 9 The NNRTI-binding pocket (BP) is hydrophobic and is lined by each of the aromatic (Y181, Y188, F227, W229 and Y232), hydrophobic (P59, L100, V106, V179, L234 and P236) and hydrophilic (K101, K103, S105, D132 and E224) amino acids of the p66 subunit and two amino acids of the p51 subunit (I135 and E138). The NNRTI-BP is only created when an inhibitor binds to the enzyme, and has not been observed in the crystal structures of unliganded RT. 10 Although it is generally accepted that NNRTIs block HIV-1 replication by inhibiting the DNA polymerase active site of RT through allosteric interaction after binding to the NNRTI-BP, recent work has suggested that effects on RT RNase H activity and/or template/primer binding might also play a role. 11, 12 NNRTI resistance is due to mutations clustered around the NNRTI-BP, often at amino acid positions 100 -110, 180 -190 and 220 -240, that substantially decrease susceptibility to all first-generation NNRTIs. 13 Recently, mutations have been described in the connection domains that can also confer NNRTI resistance. 14, 15 Among the 17 RAMs associated with etravirine resistance, the six mutations with the highest weight factor are Y181I/V/C, K101P, L100I and M230L. 8, 16, 17 Introduction of M230L into an HIV-1/HXB2 backbone by sitedirected mutagenesis (SDM) can yield etravirine resistance with a fold change (FC) varying between 3.4 and 13. 8, 18 In contrast, a recent study showed that M230L alone did not confer loss of susceptibility to either efavirenz or etravirine.
19
K103N is present in 40%-60% of patients failing NNRTIcontaining treatment regimens, 5, 16, 20 but does not confer resistance to etravirine. In the DUET studies, it was shown that K103N had no effect on the virological response (VR) to etravirine. 9 An independent study demonstrated that K103N was associated with a superior VR to etravirine. 21 Therefore, it is important to determine whether K103N confers hypersusceptibility to etravirine.
Materials and methods

Chemicals, cells and nucleic acids
The HEK293T cell line was obtained from the ATCC. The following reagents were obtained through the NIH AIDS Research and Reference Reagent Program: etravirine; efavirenz; and nevirapine. pNL4.3PFB proviral DNA was a gift from Dr Tomozumi Imamichi, NIH, Bethesda, MD, USA.
The oligonucleotides used in this study were synthesized by Integrated DNA Technologies (Coralville, Iowa) and purified by 6% polyacrylamide/7M urea gel electrophoresis. For 5 ′ -end labelling of oligonucleotides with [g-32 P]ATP, the Ambion KinaseMax TM Kit was used followed by purification through Ambion NucAway TM Spin Columns according to protocols provided by the supplier (Applied Biosystems, Streetsville, Ontario, Canada). The names and sequences of the oligonucleotides used in this study were as follows: kim40R, 5
′ -AAGCUUGGCUG CAGAAUAUUGCUAGCGGGAAUUCGGCGCG-3 ′ ; kim32D, 5 ′ -CGCGCCGAATTC CCGCTAGCAATATTCTGCAG-3 ′ ; and dPR, 5 ′ -GTCCCTGTTCGGGCGCCA-3 ′ .
Site-directed mutagenesis and preparation of virus stocks
To construct HIV-1 variants containing desired mutations in the RT gene, site-directed mutagenesis reactions were first carried out using a QuickChange II XL site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) on HIV-1 RT expression plasmid pRT6H-PROT 22 containing the wild-type (WT) RT gene from the HIV HXB2 strain. Fragments spanning RT amino acids 25 -314 from MscI and PflMI digestion from the pRT6H-PROT WT and mutant DNAs were used to replace the corresponding fragment of pNL4.3PFB proviral DNA. 23 DNA sequencing was performed in both directions across the entire RT coding region to verify the absence of spurious mutations and the presence of any desired mutation. HIV-1 WT , HIV-1 K103N and HIV-1 M230L viruses were generated by transfection of corresponding proviral plasmid DNAs into HEK293T cells using Lipofectamine 2000 (Invitrogen, Burlington, Ontario, Canada) according to the manufacturer's instructions. Viral supernatants were harvested at 48 h post-transfection, centrifuged for 5 min at 800 g to remove cellular debris, filtered through a 0.45 mM pore size filter, aliquoted and stored at 2808C. Levels of p24 in viral supernatant were measured with a Perkin Elmer HIV-1 p24 antigen ELISA kit. Virion-associated RT activity was measured as described previously, 24 with modifications as follows: 50 mL of RT reaction mixture contained 10 mL of culture supernatants, 0.5 U/mL poly(rA)/p(dT) 12 -18 
Measurements of HIV replication kinetics
Cord blood mononuclear cells (CBMCs) were isolated and cultured as previously described.
25 pNL4-3-derived WT viruses and viruses containing the K103N and M230L mutations were normalized by RT enzyme assays in order to minimize inter-inoculum effects as described previously. 26 Virus inocula were added to wells of culture plates containing CBMCs in the absence or presence of various concentrations of NNRTIs. 25 The replication kinetics of mutant and WT viral stocks were assessed on the basis of RT enzymatic activity in culture supernatants at 2 or 3 day intervals post-infection for a period of 2 weeks and viral growth kinetics were monitored by RT assay as described above.
Expression and purification of HIV-1 recombinant RT enzymes
The subtype B HIV-1 RT expression plasmid pRT6H-PROT 22 was used to create mutant pRT6H-PROT DNA constructs containing K103N and M230L. The presence of mutations and accuracy of the RT coding sequence were verified by DNA sequencing. Recombinant WT and mutated RTs were expressed and purified as described with modifications. 22, 27 In brief, RT expression in Escherichia coli M15 (pREP4) (Qiagen, Mississauga, Ontario, Canada) was induced with 1 mM IPTG at room temperature. The pelleted bacteria were lysed under native conditions with BugBuster Protein Extraction Reagent (EMD Chemicals, Gibbstown, NJ, USA) and clarified by high-speed centrifugation, and the supernatant was subjected to the batch method of Ni-NTA metal affinity chromatography using QIAexpressionist (Qiagen), according to the manufacturer's specifications. All buffers contained complete protease inhibitor cocktail (Roche). Histidine-tagged RT was eluted with an imidazole gradient. RT-containing fractions were pooled, passed through DEAE-Sepharose (GE Healthcare, Mississauga, Ontario, Canada) and further purified using SP-Sepharose (GE Healthcare). Fractions containing purified RT heterodimers were pooled, dialysed against storage buffer (50 mM Tris, pH Xu et al. 7 .8, 25 mM NaCl and 50% glycerol) and concentrated to 4-8 mg/mL with Centricon Plus-20 MWCO 30 kDa (Millipore, Etobicoke, Ontario, Canada). Protein concentration was measured using a Bradford Protein Assay Kit (Bio-Rad Laboratories, Mississauga, Ontario, Canada) and the purity of the recombinant RT preparations was verified by SDS-PAGE. The polymerase activity of each recombinant RT preparation was evaluated using varying amounts of RTs and a synthetic homopolymeric poly(rA)/ p(dT) 12 -18 template/primer (Midland Certified Reagent Company), as described previously. 28 NNRTI inhibition of RNA-dependent DNA polymerase (RDDP) activity Inhibition of RDDP activity by NNRTIs was assayed as previously reported. 28 A heterogeneous HIV primer-binding site (PBS) RNA template, containing a 497 bp HIV-1 sequence spanning the RT region of the HIV-1 long terminal repeat (LTR) and a portion of gag, was prepared in vitro with a MEGAscript transcription kit (Ambion, Austin, TX, USA) from plasmid pHIVPBS. 29 The 18 nt DNA primer dPR is complementary to the HIV-1 PBS. The template and primer were mixed at a molar ratio of 1 :3, denatured at 858C for 5 min and then sequentially cooled to 558C for 8 min and to 378C for 5 min to allow the specific annealing of primer to the template. The reaction mixture (50 mL) contained buffer, 50 mM Tris-HCL (pH 7.8), 5 mM MgC1 2 , 60 mM KC1 and 5 mM of dNTPs with 2.5 mCi of [ 3 H]dTTP (70 -80 Ci/mmol, Perkin Elmer), 100 nM heterogeneous HIV-1 PBS RNA template/dPR primer and recombinant RTs at equal activities and variable concentrations of the NNRTIs. After an incubation of 30 min at 378C, the reactions were terminated by adding 0.2 mL of 10% cold TCA and 20 mM sodium pyrophosphate and incubated for at least 30 min on ice. The precipitated products were filtered onto a 96-well MutiScreen HTS FC filter plate (Millipore). The filter plate was pre-wetted with 150 mL of assay buffer prior to use and sequentially washed with 200 mL of 10% TCA and 150 mL of 95% ethanol. The radioactivity of incorporated products was analysed by liquid scintillation spectrometry. The IC 50 s of each NNRTI were determined by non-linear regression analysis using GraphPad Prism 5.01 software.
Efficiency of synthesis of minus-strand (2) strong stop (ss) DNA The efficiency of (2)ssDNA synthesis was determined using well-established cell-free assays as described previously. 30 -33 Briefly, 20 nmol/L HPLC-purified human tRNA 3 Lys was heat-annealed to 80 nmol/L HIVcPBS RNA. PBS RNA was transcribed from PvuII-linearized pHIVcPBS DNA using a T7-MegaShortscript Kit (Ambion) as previously described. 33 Then, WT or mutated RT enzymes and 6 mmol/L MgCl 2 were added. Reactions were initiated by addition of a mixture of dNTPs to a final concentration of 10 mM of each of dATP, dGTP and dTTP and 1 mM dCTP. The efficiency of (2)ssDNA synthesis was monitored by incorporation of [a- 32 P]dCMP in time-course experiments. Aliquots of reaction mixtures were removed at various time intervals after initiation and quenched with formamide loading buffer (96% formamide, 20 mM EDTA, 0.05% xylene cyanol FF and 0.05% bromophenol blue). Samples were heat-denatured and resolved using 6% polyacrylamide/7 M urea gel electrophoresis, and analysed using a Molecular Dynamics Typhoon Phosphorimager (GE Healthcare) and ImageQuant software.
Processivity assay
The processivity of recombinant RT enzymes was studied using a heparin enzyme trap to ensure a single round of binding, primer extension and dissociation. The template/primer was prepared by annealing a 5
′ -end 32 P-labelled oligo(dT) (GE Healthcare) to an equal molar ratio of poly(rA) (GE Healthcare) homopolymeric RNA template prior to the initiation of reactions as described previously. 18 RT with an equal amount of activity and template/primer were preincubated for 5 min at 378C. Reactions were initiated by the addition of dTTP and heparin trap (final concentration 2 mg/mL) and incubated at 378C for 3 min; 2 mL of reaction mixture was removed and mixed with 8 mL of stop solution (90% formamide, 10 mM EDTA and 0.1% each of xylene cyanol FF and bromophenol blue). The effectiveness of the heparin trap to limit polymerization on the RNA template was verified in control reactions in which the heparin trap was preincubated with substrate before the addition of RT and dTTP. Reaction products were analysed by 6% denaturing PAGE and phosphorimaging.
RT-catalysed RNase H activity
DNA 3
′ -end-directed RNase H activity was assayed using a 5 ′ -end 32 P-labelled 40-mer RNA template, kim40R, annealed to a complementary 32-mer DNA primer, kim32D, 34 at a 1 : 4 molar ratio. Reactions were conducted as described previously 35 at 378C in mixtures containing RNA/DNA hybrid duplex substrate with purified RT enzymes normalized by activity in assay buffer, 50 mM Tris-HCl, pH 7.8, 50 mM NaCl, 0.1 mM EDTA, pH 8.0, and 6 mM MgCl 2 , in the absence or presence of a heparin trap at a final concentration of 2 mg/mL. RNase H cleavage was monitored in time-course experiments, with aliquots of samples removed at different timepoints after initiation of reactions and quenched by adding 3 volumes of formamide loading buffer (96% formamide, 20 mM EDTA, 0.05% xylene cyanol FF and 0.05% bromophenol blue). The samples were heated to 908C for 3 min, cooled on ice and resolved using 6% polyacrylamide/7M urea gels. The dried gels were exposed to phosphoscreens and analysed using a PhosphorImager (GE Healthcare) and ImageQuant software. The efficacy of the heparin trap was verified by pre-incubation experiments performed through a 10 min pre-incubation of RT enzymes with various concentrations of heparin trap followed by initiation with the [ 32 P]RNA/DNA hybrid duplex substrate and magnesium in the same assay buffer as described above.
Results
Effects of the K103N and M230L RT mutations on viral replication kinetics in CBMCs
It was recently shown that the M230L mutation in an HXB2 genetic background did not confer either a loss of susceptibility to etravirine or a significant decrease in viral replication capacity. 19 To address this inconsistency with our own published work, 18 we constructed a series of NL4-3-derived viruses in which the RT fragment spanning amino acids 25-314 was replaced by HXB2 RT sequences.
Multi-cycle replication kinetics of WT and mutant viruses were measured and compared in CBMC cultures, 36 in which quantification of virus production at various timepoints was carried out, i.e. p24 CA antigen or RT activity. 36, 37 The results in Figure 1 show that K103N viruses replicated as well as did WT viruses in the absence of NNRTIs, while the M230L viruses replicated much more poorly. In the presence of drug (i.e. 10 nM etravirine and efavirenz, and 1 mM nevirapine), M230L virus displayed substantial replication capacity while WT virus was fully inhibited. At the highest concentrations of NNRTIs tested, only the K103N virus showed substantial replication ability in the presence of efavirenz and nevirapine, while only M230L virus could grow in the presence of 10 nM etravirine. These results confirm that M230L confers both resistance to etravirine as well as lower replication capacity compared with HIV-1 RT mutations K103N and M230L 2293 JAC K103N and WT viruses, consistent with previous results using TZM-BL cells. 18 
Purification of recombinant HIV-1 heterodimeric RT enzyme
Recombinant WT RT heterodimer (p66/p51) and RT enzymes containing either the K103N or M230L substitutions were purified to .95% homogeneity; the RT p66 and p51 subunits were processed to similar molar ratios based on SDS-PAGE analysis (Figure 2 ). The mutations introduced did not interfere with either heterodimer formation or enzyme purification.
Inhibitory effects of NNRTIs in RDDP RT filter-binding assays
The inhibitory effects of various NNRTIs on RDDP activity were measured by a filter-binding RT assay using HIV-1 PBS RNA template. This assay reflects physiologically relevant conditions compared with the use of commonly used homopolymeric . Viruses were harvested from transfection of HEK293T cells and were used to infect CBMCs by normalizing the inoculum as described in the Materials and methods section. Three concentrations were used for each NNRTI: ETR and EFV, 1, 10 and 100 nM; and NVP, 0.1, 1 and 10 mM. Virus production was monitored at the indicated timepoints by assaying RT activity in cell-free supernatants.
poly(rA)/oligo(dT) substrate. 12 Susceptibilities of WTand mutant RTs were determined for each of etravirine, efavirenz and nevirapine ( Table 1 ). The results show that both K103N and M230L RTs displayed high-level resistance to efavirenz and nevirapine. The fold change (FC) for efavirenz ranged from approximately 15 for M230L RT to 39 for K103N RT, while for nevirapine the FCs ranged from 33 for M230L to 43 for K103N RT. The M230L RT conferred 8-fold resistance to etravirine, consistent with results obtained using homogeneous poly(rA) template/oligo(dT) primer, 18 while the K103N mutant RT showed an FC of 0.7 compared with WT enzyme. Thus, recombinant RT harbouring K103N is as susceptible as WT enzyme to etravirine. We also observed an FC of 0.7 in susceptibility to etravirine using K103N RT in the CBMC phenotyping assay (H.-T. Xu and M. A. Wainberg, unpublished results). It is known that K103N is associated with a 0.5 FC for etravirine. 8 Effect of K103N and M230L on efficiency of (2)ssDNA synthesis
We next used human tRNA 3 Lys as primer in reactions in which the latter was annealed to the PBS near the 5 ′ -end of viral RNA to study synthesis of (2)ssDNA. 30, 31, 33, 38, 39 Previous results showed that the G190S and G190A mutations impaired efficiency of tRNA-primed (2)ssDNA synthesis. 38 Now, timecourse reactions involving M230L RT and K103N RT yielded less product than those performed with WT RT and the decrease in formation of full-length DNA products was pronounced at all timepoints in these experiments (Figure 3) . Thus, M230L leads to both diminished levels of tRNA-primed synthesis of (2)ssDNA as well as a loss of viral replication efficiency.
Processivity of RTs containing K103N and M230L
The processivity of a polymerase is defined as the number of nucleotides incorporated in a single round of binding, elongation and dissociation. 40 -44 To compare the impact of the K103N and M230L mutations on enzyme processivity, we tested the WT and mutant RTs using homopolymeric poly(rA) RNA template annealed to 5
′ -end 32 P-labelled oligo(dT) primers in a fixed-time experiment in the presence of a heparin trap to ensure that each synthesized DNA molecule resulted from a single processive cycle. Figure 4 shows that the M230L mutation caused decreased processivity, the longest products made having a size of 100 nt, while the WT enzyme yielded products of 200 nt, as did the K103N enzyme. Thus, RT containing M230L 
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2295 JAC is much less processive than WT enzyme, while K103N does not seem to affect enzyme processivity significantly.
RNase H activity
Substitutions at residues near or adjacent to the primer grip of RT can impair RNase H activity and contribute to reductions in HIV-1 replication fitness, 45, 46 and some NNRTI resistance mutations are associated with impaired RNase H activity. 38,47 -50 Furthermore, reduced RNase H activity might sometimes enhance NNRTI resistance. 51 In particular, K103N was reported to possess normal RNA 5 ′ -end-directed RNase H cleavage, but slower DNA 3 ′ -end-directed RNase H cleavage, compared with WT RT. 45 We monitored multi-cycle and single-cycle RNase H-mediated RNA cleavage in time-course experiments using a 3 ′ -recessed DNA primer hybridized to a 5 ′ -end-labelled RNA to study DNA 3 ′ -end-directed RNase H activity in the presence or absence of a heparin trap. In the absence of the heparin trap, both the K103N and M230L RTs produced the same cleavage profiles as WT enzyme ( Figure 5 ). The first cleavage at the 218 position relative to the 3 ′ -end of the DNA primer indicates the distance of the active sites of polymerase and RNase H, showing that the RNA template is cleaved 18 nt upstream of the 3 ′ -end of the primer terminus. 35 The second cleavage at the 215 position appears very soon after the first cleavage and also appears in the trap reaction, indicating that the RT enzyme does not dissociate from the substrate, but slides 3 nt toward the 3 ′ -end of the primer for this cut. The third cleavage product at the 27 position does not appear in the trap reaction, indicating that the RT enzymes need to rebind to the substrate after dissociation for this cleavage. These results show that the K103N and M230L substitutions introduced into RT did not substantially change the spatial and temporal relationships between the active sites of polymerase and RNase H components of RT ( Figure 5 ).
The RNase H activity of M230L RT was much lower than that of WT RT and K103N RT, both in the absence and presence of trap, as indicated by accumulation of the 27 and 215 cleavage products, respectively. M230L resulted in decreased cleavage efficiency compared with WT RT, indicating that this mutation impairs RNase H activity. Compared with M230L RT, K103N showed much higher cleavage efficiency under both conditions, but slightly lower than WT enzyme, consistent with previous reports showing that K103N slows DNA 3 ′ -end-directed RNase H cleavage. 45 
Discussion
This study compared the K103N and M230L mutations with regard to RT enzyme function and biochemical inhibitory activities with regard to nevirapine, efavirenz and etravirine. In addition, the effects of these mutations on viral growth properties in the absence and presence of NNRTIs were studied in CBMC cultures.
K103N is the most common mutation that emerges in patients who fail the first-generation NNRTIs efavirenz and nevirapine, while M230L is less prevalent in clinical settings. We have shown that M230L, introduced into chimeric HIV-1NL43 virus, caused a significant reduction in viral replication capacity, unlike K103N virus, and that the latter virus has similar replication kinetics to WT virus, consistent with previous reports.
18,38,52 M230L RT enzyme was also deficient with regard to each of (2)DNA synthesis, processivity and RNase H activity, while K103N enzyme behaved similarly to WT, consistent with previous reports. 18, 38 Although both residues are located around the NNRTI-BP, the K103N and M230L mutations have differential NNRTI resistance profiles. Our data provide further evidence confirming that M230L confers resistance to all currently available NNRTIs, consistent with previous reports. 18, 53 Structural studies of HIV-1 RT have shed light on mechanisms of NNRTI resistance. 54 K103 is located in the b5-b6 connecting loop near the entrance of the NNRTI-BP. Structural studies of K103N suggest that an extra hydrogen bond within the collapsed NNRTI-BP between N103 and Y188 side chains is created, making P at the 5 ′ -terminus and annealed to a poly(rA) RNA template at an equimolar ratio. Processivity was analysed by monitoring the size distribution of DNA synthesis in fixed-time experiments in the presence of a heparin trap (+). Parallel reactions were run in the absence of trap (2) to ensure that similar amounts of enzyme activities were used in the reactions. C1, control reaction without RT enzyme showing the position and integrity of labelled primer. C2, control reaction to verify the efficiency of the heparin trap by pre-incubation with substrate prior to addition of WT RT. The sizes (bases) of fragments of a DNA molecular weight standard are indicated on the right. All reaction products were resolved using denaturing 6% PAGE and visualized by phosphorimaging.
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it difficult for rigid first-generation NNRTIs to enter the hydrophobic NNRTI-BP, 55, 56 thus conferring cross-resistance. Recent co-crystal structures of K103N mutant RT in complex with etravirine have shown that etravirine binds and adapts to changes in the NNRTI-BP. 4, 6 Although hypersusceptibility of K103N RT to etravirine was not demonstrated based on the fact that hypersusceptibility to NNRTI was generally defined as an FC in IC 50 of ,0.4, 13 we observed an FC of 0.7 in IC 50 for K103N against etravirine using an RDDP RT enzyme assay performed on an HIV-1 PBS RNA template with a PBS DNA primer, compared with that of the WT enzyme, confirming that K103N is fully susceptible to etravirine. 8 These data are in support of recent studies showing that K103N was associated with a better VR to etravirine. 21 The M230 residue is located at the loop of the b12 -b13 hairpin, comprising amino acids 227 -235 (FLWMGYELH), which defines the so-called primer grip, playing important roles in both RT enzyme function and formation of the NNRTI binding pocket. The primer grip helps to maintain the primer terminus in an orientation appropriate for nucleophilic attack on an incoming dNTP. 57 Recently, an NMR study of HIV-1 RT both in the presence and absence of nevirapine showed that M230 in the p66 subunit is more mobile and solvent-exposed than suggested by crystal structures of the apo enzyme, which have a 'closed' fingers -thumb conformation. 58 This mobility of the primer grip is presumably important for binding of NNRTIs, since the NNRTI-BP is not observed in the absence of the inhibitors, requiring instead that the BP be dynamically accessible. 58 The M230L substitution might affect this mobility and influence the formation of the NNRTI-BP. By doing so, it might interfere with NNRTI binding and cause drug resistance. Mutational analysis of primer grip residues has shown their influence on various RT functions, including dNTP binding, 59 polypurine tract removal, 60 RNase H activity, 46 template/primer utilization 57, 61 and fidelity of DNA synthesis. 62 -64 Virus containing an M230A substitution was shown to be non-infectious. 65 The biochemical data presented here show that the impairment in enzyme function associated with M230L contributes to reduced viral replication. However, an M230I mutation was able to compensate for a Y115W substitution, restoring viral replication capacity, 66 whereas Y115W impaired RT activity by decreasing the dNTP binding affinity of the polymerase. Thus, different substitutions at M230 may have different effects on viral replication and RT function. Biochemical investigation of the interplay of M230L with other NNRTI and/or NRTI mutations is under way in our laboratory.
In summary, the differential impacts associated with K103N and M230L help to explain differences in the evolution and prevalence of these two NNRTI mutations. Although the prevalence of the M230L mutation in the clinic is still low, future studies may well reveal that M230L is a key mutation with regard to etravirine and possibly other second-generation NNRTIs as well. While other NNRTI mutations may also impact on viral susceptibility to etravirine and other secondgeneration NNRTIs, as observed in the DUET trial, 9 it is also possible that the relatively low prevalence of M230L may be attributable to its ability to hypersensitize to certain nucleoside drugs, such as zidovudine and lamivudine, 9, 67 and the resultant enhanced activity of such compounds against M230L-containing viruses. 
